AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18561930 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential ablation with focal ablation
Number of subjects: 70
Study 18564200 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA-defined metabolic syndrome
Number of subjects: 320
Study 18564200 — intervention group
Group type: EXPERIMENTAL
Intervention: IDF-defined metabolic syndrome
Number of subjects: 320
Study 18565399 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR)
Number of subjects: 65
Study 18565399 — intervention group
Group type: COMPARATOR
Intervention: No late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR)
Number of subjects: 65
Study 18565793 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 106
Study 18565861 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe ECG abnormality
Number of subjects: 406
Study 18565861 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of atrial tachyarrhythmia
Number of subjects: 406
Study 18565861 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 406
Study 18569235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients citing drawbacks about asthma medications
Number of subjects: 52
Study 18569235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients citing benefits about asthma medications
Number of subjects: 52
Study 18569235 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with asthma (overall population)
Number of subjects: 52
Study 18572984 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 10
Study 18580170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia (66% for at least 2 hours)
Number of subjects: 140
Study 18582195 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A vaccination
Number of subjects: 24
Study 18582371 — intervention group
Group type: EXPERIMENTAL
Intervention: The Treatment Perspective (16 week supervised training intervention including motivational counselling)
Number of subjects: 0
Study 18582371 — intervention group
Group type: COMPARATOR
Intervention: The Preventive Perspective (only motivational counselling)
Number of subjects: 0
Study 18583924 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18584946 — intervention group
Group type: COMPARATOR
Intervention: Antimuscarinics (tolterodine ER 4 mg once daily)
Number of subjects: 229
Study 18584946 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinics (tolterodine ER 4 mg once daily) + local oestrogens (oestriol cream application once daily)
Number of subjects: 229
Study 18589337 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-independent telemedicine system used by telemedicine-naive examiners
Number of subjects: 25
Study 18591547 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily)
Number of subjects: 34
Study 18591942 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous 1,25-dihydroxyvitamin D administration
Number of subjects: 0
Study 18592321 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalists
Number of subjects: 372
Study 18593770 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-long-acting release (LAR) therapy at a dose of 20 mg every 28 days for 3 months
Number of subjects: 67
Study 18593770 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-long-acting release (LAR) therapy
Number of subjects: 67
Study 18596230 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD22 levels in patients with HCL
Number of subjects: 93
Study 18596272 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib diphosphate (125 mg, orally once daily)
Number of subjects: 93
Study 18598190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine
Number of subjects: 1699
Study 18598190 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) prophylaxis
Number of subjects: 1699
Study 18598362 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (ABM MC) transplantation, 100 x 10^6 MC suspended in saline with 5% autologous serum
Number of subjects: 300
Study 18598362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline with 5% autologous serum)
Number of subjects: 300
Study 18598891 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HT)
Number of subjects: 27736
Study 18598891 — intervention group
Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy (Control)
Number of subjects: 27736
Study 18603291 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal CPR
Number of subjects: 975
Study 18603291 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 975
Study 18606624 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with enterovirus 71 infection
Number of subjects: 86
Study 18606624 — intervention group
Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 86
Study 18606979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (original DCCT treatment group assignment)
Number of subjects: 249
Study 18606979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean A1C values
Number of subjects: 249
Study 18606979 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycemic events
Number of subjects: 249
Study 18606979 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment group
Number of subjects: 249
Study 18612103 — intervention group
Group type: EXPERIMENTAL
Intervention: Second autologous stem cell transplantation (ASCT)
Number of subjects: 110
Study 18612103 — intervention group
Group type: COMPARATOR
Intervention: Reduced-intensity-conditioning allograft (allo-RIC)
Number of subjects: 110
Study 18612102 — intervention group
Group type: EXPERIMENTAL
Intervention: dmCODOX-M (methotrexate, dose 3 g/m(2)) with or without IVAC
Number of subjects: 128
Study 18615166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 34
Study 18615166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18615172 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day) for 8 weeks
Number of subjects: 17
Study 18615176 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 to 120 mg)
Number of subjects: 840
Study 18617067 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of beta-blockers (1,350 patients, 56.9%)
Number of subjects: 5791
Study 18617067 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of beta-blockers (79 patients, 3.3%)
Number of subjects: 5791
Study 18617067 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker therapy (303 patients, 12.8%)
Number of subjects: 5791
Study 18617067 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly started beta-blockers (632 patients, 26.6%)
Number of subjects: 5791
Study 18619571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab
Number of subjects: 79
Study 18619874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide 100mg/day, escalated by 100mg/day to a maximum of 400mg/day during the 20-week maintenance period and continued for up to 2.5 years in the extension period.
Number of subjects: 69
Study 18619874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide treatment during the study.
Number of subjects: 69
Study 18619874 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide treatment at study termination.
Number of subjects: 69
Study 18620563 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized addiction treatment plus treatment as usual
Number of subjects: 0
Study 18620563 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 18621618 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus lapatinib
Number of subjects: 0
Study 18621618 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus trastuzumab
Number of subjects: 0
Study 18621618 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus both lapatinib and trastuzumab
Number of subjects: 0
Study 18623174 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 105
Study 18623174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 18625666 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for > or = 4 h/night
Number of subjects: 32
Study 18625666 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for < 4 h/night
Number of subjects: 32
Study 18625762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lopinavir-ritonavir (LPV/r) 400/100 mg/m(2) p.o. q12h without NNRTI
Number of subjects: 26
Study 18625762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lopinavir-ritonavir (LPV/r) 480/120 mg/m(2) p.o. q12h with NNRTI
Number of subjects: 26
Study 18625762 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV) 750 mg/m(2) p.o. q12h added when LPV IQ <15
Number of subjects: 26
Study 18625762 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (LPV/r with or without SQV)
Number of subjects: 26
Study 18626272 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (20, 25, or 30 mg/d)
Number of subjects: 21
Study 18626272 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (maximum dose for cohort for 14 days)
Number of subjects: 21
Study 18627059 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing pursued by 83 individuals (8.3%)
Number of subjects: 1001
Study 18627059 — intervention group
Group type: COMPARATOR
Intervention: Individuals who did not pursue genetic testing
Number of subjects: 1001
Study 18627059 — intervention group
Group type: EXPERIMENTAL
Intervention: United States residents who pursued genetic testing
Number of subjects: 1001
Study 18627059 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian residents who pursued genetic testing
Number of subjects: 1001
Study 18628574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-meal tolerance test (MMTT)
Number of subjects: 266
Study 18628574 — intervention group
Group type: COMPARATOR
Intervention: Glucagon stimulation test (GST)
Number of subjects: 266
Study 18633105 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction immunosuppression followed by sirolimus and tacrolimus (no glucocorticoids)
Number of subjects: 7
Study 18635429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin and rituximab
Number of subjects: 20
Study 18635722 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg/day
Number of subjects: 984
Study 18635722 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-225 mg/day
Number of subjects: 984
Study 18635722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 18639220 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant insertion combined with phacoemulsification and intraocular lens implantation
Number of subjects: 21
Study 18640325 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative neurocognitive dysfunction
Number of subjects: 113
Study 18640325 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 113
Study 18640325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild atherosclerosis of the ascending aorta
Number of subjects: 113
Study 18640325 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of cardiopulmonary bypass (CPB)
Number of subjects: 113
Study 18640325 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of aortic cross-clamping
Number of subjects: 113
Study 18640325 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of postoperative hospitalization
Number of subjects: 113
Study 18640325 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein epsilon4 genotype
Number of subjects: 113
Study 18641094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen use
Number of subjects: 1215
Study 18641094 — intervention group
Group type: COMPARATOR
Intervention: Nonhypoxemic individuals not using oxygen
Number of subjects: 1215
Study 18641097 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese subjects (BMI > or = 30 kg/m(2))
Number of subjects: 88
Study 18641097 — intervention group
Group type: COMPARATOR
Intervention: Nonobese subjects (BMI < 25 kg/m(2))
Number of subjects: 88
Study 18641112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary source of sepsis
Number of subjects: 288
Study 18641112 — intervention group
Group type: COMPARATOR
Intervention: Nonpulmonary source of sepsis
Number of subjects: 288
Study 18641112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vs nonpulmonary source of sepsis
Number of subjects: 288
Study 18643743 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and tigecycline catheter-lock solution for 14 days plus systemic antibiotic therapy
Number of subjects: 18
Study 18644065 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 72
Study 18644065 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 72
Study 18647805 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in women with PCOS
Number of subjects: 52
Study 18647805 — intervention group
Group type: COMPARATOR
Intervention: No OSA (control group)
Number of subjects: 52
Study 18650451 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN-alpha-2a
Number of subjects: 40
Study 18650621 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon-based chemoradiation followed by gemcitabine
Number of subjects: 53
Study 18650621 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (interferon- and gemcitabine-based)
Number of subjects: 53
Study 18651943 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for cancer-related fatigue (CRF)
Number of subjects: 300
Study 18651943 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 300
Study 18652942 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients hospitalized with HF
Number of subjects: 48612
Study 18652942 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-prediction algorithm for in-hospital mortality
Number of subjects: 48612
Study 18652943 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 1000
Study 18656877 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese juveniles
Number of subjects: 71
Study 18656877 — intervention group
Group type: COMPARATOR
Intervention: Normal weight controls
Number of subjects: 71
Study 18657709 — intervention group
Group type: COMPARATOR
Intervention: Single-dose nevirapine (200 mg to women in labour and 2 mg/kg to newborns after birth)
Number of subjects: 2024
Study 18657709 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-dose nevirapine (200 mg to women in labour and 2 mg/kg to newborns after birth plus 5 mg daily from days 8-42 for the infant)
Number of subjects: 2024
Study 18657796 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (GDx-VCC)
Number of subjects: 109
Study 18657796 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (Stratus OCT)
Number of subjects: 109
Study 18657796 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal scanning laser ophthalmoscopy (HRT II)
Number of subjects: 109
Study 18662932 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week for up to 20 weeks
Number of subjects: 1250
Study 18663426 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine plus alpha-lipoic acid
Number of subjects: 9
Study 18663532 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted gastrectomy (LAG)
Number of subjects: 1485
Study 18668591 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1 Trap) 300 mg loading dose, followed by maintenance doses of 100 mg/week, with possible escalation to 160 mg/week and 320 mg/week.
Number of subjects: 5
Study 18668591 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1 Trap) 100 mg/week and higher doses (160 mg and 320 mg).
Number of subjects: 5
Study 18668591 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1 Trap) at higher doses (160 mg and 320 mg).
Number of subjects: 5
Study 18668591 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (IL-1 Trap).
Number of subjects: 5
Study 18668653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg by mouth every 8 hours for 6 weeks (initial 2-week titration).
Number of subjects: 9
Study 18668653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline treatment.
Number of subjects: 9
Study 18669874 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (THAL, 200 mg/d) with monthly pamidronate
Number of subjects: 76
Study 18669874 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial response (PR) status
Number of subjects: 76
Study 18669874 — intervention group
Group type: EXPERIMENTAL
Intervention: Low beta-2-microglobulin levels less than 2 mg/L
Number of subjects: 76
Study 18669874 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival and event-free survival estimates
Number of subjects: 76
Study 18669874 — intervention group
Group type: EXPERIMENTAL
Intervention: Postsalvage therapy
Number of subjects: 76
Study 18669875 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD negative patients at day 100 after ASCT
Number of subjects: 295
Study 18669875 — intervention group
Group type: COMPARATOR
Intervention: MRD positive patients at day 100 after ASCT
Number of subjects: 295
Study 18669875 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD(-) immunofixation-negative (IFx(-)) patients
Number of subjects: 295
Study 18669875 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD(-) immunofixation-positive (IFx(+)) patients
Number of subjects: 295
Study 18669875 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD status by MFC at day 100 after ASCT
Number of subjects: 295
Study 18671877 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (10 g of gel containing 100 mg of testosterone)
Number of subjects: 10
Study 18673542 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive cardiac imaging algorithm followed by evidence-based treatment (including CT calcium scoring, CT angiography, and DSMR testing)
Number of subjects: 1200
Study 18673542 — intervention group
Group type: COMPARATOR
Intervention: CT calcium scoring (control group)
Number of subjects: 1200
Study 18675557 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic femoro-popliteal bypass
Number of subjects: 100
Study 18681756 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram, starting at 20 mg/day, increased to 40 mg/day by weeks 2-4, and to 60 mg/day by weeks 4-6.
Number of subjects: 2851
Study 18681756 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment.
Number of subjects: 2851
Study 18681768 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 18682513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (1.3 +/- 1.3 mg/wk, treatment duration 12-60 months in 32%, >60 months in 68%)
Number of subjects: 50
Study 18682513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (cumulative dose above median)
Number of subjects: 50
Study 18682513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (cumulative dose below median)
Number of subjects: 50
Study 18682513 — intervention group
Group type: COMPARATOR
Intervention: De novo patients
Number of subjects: 50
Study 18682513 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 50
Study 18682973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
Number of subjects: 6
Study 18684848 — intervention group
Group type: EXPERIMENTAL
Intervention: IBV(R) Valves (Spiration, Inc.) placed to occlude segmental and subsegmental bronchi in right and left upper lobes
Number of subjects: 57
Study 18684848 — intervention group
Group type: EXPERIMENTAL
Intervention: IBV(R) Valves (Spiration, Inc.)
Number of subjects: 57
Study 18687247 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed measurement of immunoreactive B-type natriuretic peptide (iBNP) levels
Number of subjects: 58465
Study 18687247 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer time to treatment
Number of subjects: 58465
Study 18687247 — intervention group
Group type: EXPERIMENTAL
Intervention: Rales on initial examination
Number of subjects: 58465
Study 18687247 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer average time to iBNP draw
Number of subjects: 58465
Study 18687247 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment delay
Number of subjects: 58465
Study 18687248 — intervention group
Group type: EXPERIMENTAL
Intervention: PREPARE programming
Number of subjects: 700
Study 18687248 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (EMPIRIC and MIRACLE ICD trials)
Number of subjects: 700
Study 18687721 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura
Number of subjects: 27519
Study 18687721 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura in lowest Framingham risk score group
Number of subjects: 27519
Study 18687721 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura in highest Framingham risk score group
Number of subjects: 27519
Study 18687721 — intervention group
Group type: COMPARATOR
Intervention: Women without migraine
Number of subjects: 27519
Study 18687759 — intervention group
Group type: EXPERIMENTAL
Intervention: Single SBP measurements
Number of subjects: 5140
Study 18687759 — intervention group
Group type: EXPERIMENTAL
Intervention: Two SBP measurements at each site
Number of subjects: 5140
Study 18687759 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of low ABI
Number of subjects: 5140
Study 18687759 — intervention group
Group type: EXPERIMENTAL
Intervention: Average leg ABI
Number of subjects: 5140
Study 18693069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabone cord-blood transplantation
Number of subjects: 32